The approval of the combination for first-line use means that it is now the treatment of choice for the disease. Oddly, this news may account for the late day rally last Friday in Nuvilex, Inc.'s (OTCQB: NVLX) shares as they very well could be next in line to approach the FDA with even better data than Celgene.
News 
Market Data 
Discover 
